Download PDF
Horm Metab Res 2013; 45(02): 147-153
DOI: 10.1055/s-0032-1331211
Review
© Georg Thieme Verlag KG Stuttgart · New York

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB Tumors

J. Matro
1   Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
2   Faculty of Pharmacy and Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines
,
A. Giubellino
1   Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
,
K. Pacak
1   Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
› Author Affiliations
Further Information

Publication History

received 01 August 2012

accepted 06 November 2012

Publication Date:
15 January 2013 (online)

Also available at
    Permissions and Reprints

Abstract

As a result of intense genetic studies of families with specific mutations, the road to better therapeutic intervention for pheochromocytoma (PHEOs) and parangangliomas (PGLs) has more recently become populated with several promising molecular targets. Consequently a change in paradigm from a previous view on nonspecific therapy has shifted towards more selective molecular targeted therapies. In particular, malignant PHEOs/PGLs, more specifically the tumors that result from mutations in succinate dehydrogenase subunit B (SDHB), are a clear concern, and novel therapies should be developed to address this problem. Here we summarize current and future therapeutic approaches.

Key words

pheochromocytoma - paraganglioma - SDHB - therapy
 

  • References

  • 1 Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: 367-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Fliedner SM, Lehnert H, Pacak K. Metastatic paraganglioma. Sem Oncol 2010; 37: 627-637
    CrossrefPubMedGoogle Scholar
  • 3 Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, Linehan WM, Pacak K. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011; 57: 411-420
    CrossrefPubMedGoogle Scholar
  • 4 Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113: 2020-2028
    CrossrefPubMedGoogle Scholar
  • 5 Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007; 92: 1217-1225
    CrossrefPubMedGoogle Scholar
  • 6 Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTR inhibitor everolimus (RAD001). Horm Metab Res 2009; 41: 697-702
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41: 687-696
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, Gross MD, Carey JE, Zasadny KR, Beierwaltes WH. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991; 35: 269-276
    PubMedGoogle Scholar
  • 9 Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): acomprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648-658
    CrossrefPubMedGoogle Scholar
  • 10 Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27: 4162-4168
    CrossrefPubMedGoogle Scholar
  • 11 Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Quart J Nucl Med Mol Imag 2008; 52: 419-429
    PubMedGoogle Scholar
  • 12 Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-related cancer 2012; 19: 83-93
    PubMedGoogle Scholar
  • 13 Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 2011; 18: 104-112
    PubMedGoogle Scholar
  • 14 Gimenez-Roqueplo AP, Dahia PL, Robledo M. An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes. Horm Metab Res 2012; 44: 328-333
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Burnichon N, Lepoutre-Lussey C, Laffaire J, Gadessaud N, Molinie V, Hernigou A, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur J Endocrinol 2011; 164: 141-145
    CrossrefPubMedGoogle Scholar
  • 16 Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000; 275: 3568-3576
    CrossrefPubMedGoogle Scholar
  • 17 Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, McArthur GA. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 2008; 112: 2305-2317
    CrossrefPubMedGoogle Scholar
  • 18 Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318
    CrossrefPubMedGoogle Scholar
  • 19 Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mechanisms of development 1998; 73: 117-123
    CrossrefPubMedGoogle Scholar
  • 20 Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686
    CrossrefPubMedGoogle Scholar
  • 21 Dutta D, Ray S, Vivian JL, Paul S. Activation of the VEGFR1 chromatin domain: an angiogenic signal-ETS1/HIF-2alpha regulatory axis. J Biol Chem 2008; 283: 25404-25413
    CrossrefPubMedGoogle Scholar
  • 22 Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, Spruyt N, Soncin F. HIF 2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 2007; 26: 7480-7489
    CrossrefPubMedGoogle Scholar
  • 23 Eubank TD, Roda JM, Liu H, O’Neil T, Marsh CB. Opposing roles for HIF-1alpha and HIF-2alpha in the regulation of angiogenesis by mononuclear phagocytes. Blood 2011; 117: 323-332
    CrossrefPubMedGoogle Scholar
  • 24 Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical. Mol Cell 2010; 29: 435-442
    CrossrefPubMedGoogle Scholar
  • 25 Maher ER. Genetics of phaeochromocytoma. Br Med Bull 2006; 79–80: 141-151
    PubMedGoogle Scholar
  • 26 Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskela S, Maliszewska A, Inglada-Perez L, de la Vega L, Rodriguez-Antona C, Leton R, Bernal C, de Campos JM, Diez-Tascon C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascon A. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010; 24: 2382-2391
    CrossrefPubMedGoogle Scholar
  • 27 Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo RA, Toledo SP, Stiles C, Aguiar RC, Dahia PL. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Gen 2010; 42: 229-233
    CrossrefPubMedGoogle Scholar
  • 28 Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and cellular biology 2002; 22: 7004-7014
    CrossrefPubMedGoogle Scholar
  • 29 Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007; 282: 20534-20543
    CrossrefPubMedGoogle Scholar
  • 30 Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008; 283: 34495-34499
    CrossrefPubMedGoogle Scholar
  • 31 Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. The Journal of pathology 2010; 221: 125-138
    CrossrefPubMedGoogle Scholar
  • 32 Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074
    PubMedGoogle Scholar
  • 33 Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, Martiniova L, Lubensky IA, Lisanti MP, Picard KL, Powers JF, Tischler AS, Pacak K, Albanese C. ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle 2007; 6: 1946-1950
    CrossrefPubMedGoogle Scholar
  • 34 Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101
    CrossrefPubMedGoogle Scholar
  • 35 Gujral TS, Mulligan LM. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann N Y Acad Sci 2006; 1073: 234-240
    CrossrefPubMedGoogle Scholar
  • 36 Powers JF, Schelling K, Brachold JM, Tsokas P, Schayek H, Friedman E, Tischler AS. High-level expression of receptor tyrosine kinase Ret and responsiveness to Ret activating ligands in pheochromocytoma cell lines from neurofibromatosis knockout mice. Mol Cell Neurosci 2002; 20: 382-389
    CrossrefPubMedGoogle Scholar
  • 37 Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 2010; 31: 578-599
    CrossrefPubMedGoogle Scholar
  • 38 Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993; 119: 1005-1017
    PubMedGoogle Scholar
  • 39 Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16: 441-467
    CrossrefPubMedGoogle Scholar
  • 40 Panta GR, Nwariaku F, Kim LT. RET signals through focal adhesion kinase in medullary thyroid cancer cells. Surgery 2004; 136: 1212-1217
    CrossrefPubMedGoogle Scholar
  • 41 Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype phenotype relationship. Arch Surg 2003; 138: 409-416 discussion 416
    CrossrefPubMedGoogle Scholar
  • 42 Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem 2011; 18: 162-175
    CrossrefPubMedGoogle Scholar
  • 43 Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol 2011; 39: 271-278
    PubMedGoogle Scholar
  • 44 Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Rel Cancer 2011; 18: 1-11
    PubMedGoogle Scholar
  • 45 Liu Q, Djuricin G, Staren ED, Gattuso P, Gould VE, Shen J, Saclarides T, Rubin DB, Prinz RA. Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 1996; 120: 938-942 discussion 942–933
    CrossrefPubMedGoogle Scholar
  • 46 Claffey KP, Wilkison WO, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992; 267: 16317-16322
    PubMedGoogle Scholar
  • 47 Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC, Zielke A. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 2002; 110: 386-392
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, Nakai T, Okuda Y. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 2004; 74: 863-871
    CrossrefPubMedGoogle Scholar
  • 49 Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC, Duh QY. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 2002; 132: 1056-1063 discussion 1063
    CrossrefPubMedGoogle Scholar
  • 50 Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, Seito T, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R. Expression of the c-kit protein in human solid tumors and incorresponding fetal and adult normal tissues. Am J Pathol 1993; 142: 339-346
    PubMedGoogle Scholar
  • 51 Tavangar SM, Shojaee A, Moradi Tabriz H, Haghpanah V, Larijani B, Heshmat R, Lashkari A, Azimi S. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract 2010; 206: 305-309
    CrossrefPubMedGoogle Scholar
  • 52 Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?. Ann N Y Acad Sci 2006; 1073: 517-526
    CrossrefPubMedGoogle Scholar
  • 53 Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G. Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocrine related cancer 2008; 15: 343-350
    CrossrefPubMedGoogle Scholar
  • 54 Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease related tumors. J Clin Endocrinol Metab 2009; 94: 386-391
    CrossrefPubMedGoogle Scholar
  • 55 Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U, Maher ER, Grone HJ, Eckardt KU. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-5222
    PubMedGoogle Scholar
  • 56 Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews Cancer 2003; 3: 721-732
    CrossrefPubMedGoogle Scholar
  • 57 Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225-233
    CrossrefPubMedGoogle Scholar
  • 58 Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer research 2010; 70: 1053-1062
    CrossrefPubMedGoogle Scholar
  • 59 Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-528
    CrossrefPubMedGoogle Scholar
  • 60 McLaughlin SH, Ventouras LA, Lobbezoo B, Jackson SE. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J Mol Biol 2004; 344: 813-826
    CrossrefPubMedGoogle Scholar
  • 61 Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410
    CrossrefPubMedGoogle Scholar
  • 62 Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-549
    CrossrefPubMedGoogle Scholar
  • 63 Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang Vu C, Roessner A, Lehnert H. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003; 88: 4280-4286
    CrossrefPubMedGoogle Scholar
  • 64 Pacak K. Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul 2011; 45: 65-90
    CrossrefPubMedGoogle Scholar
  • 65 Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 2011; 18: 104-112
    PubMedGoogle Scholar
  • 66 Martiniova L, Lu J, Chiang J, Bernardo M, Lonser R, Zhuang Z, Pacak K. Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PloS one 2011; 6: e14678
    CrossrefPubMedGoogle Scholar
  • 67 Murthy SR, Pacak K, Loh YP. Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. Cell Mol Neurobiol 2010; 30: 1377-1381
    CrossrefPubMedGoogle Scholar
  • 68 Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, Wesley RA, Ng IO, Pacak K, Poon RT, Loh YP. An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest 2011; 121: 880-892
    CrossrefPubMedGoogle Scholar
  • 69 Ahn J, Sanz-Moreno V, Marshall CJ. The metastasis gene NEDD9 product acts through integrin beta3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci 2012; 125: 1814-1826
    CrossrefPubMedGoogle Scholar
  • 70 Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005; 8: 155-167
    CrossrefPubMedGoogle Scholar
  • 71 Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin Jr WG. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Gen Develop 2008; 22: 884-893
    CrossrefPubMedGoogle Scholar
  • 72 Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K. Increased uptake of [(1)(2)(3)I]meta-iodobenzylguanidine, [(1)(8)F]fluorodopamine, and [(3)H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Rel Cancer 2011; 18: 143-157
    CrossrefPubMedGoogle Scholar
  • 73 Pacak K, Sirova M, Giubellino A, Lencesova L, Csaderova L, Laukova M, Hudecova S, Krizanova O. NF-kappaB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer 2012; 131: 2445-2455
    CrossrefPubMedGoogle Scholar
  • 74 Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 2007; 14: 1204-1206
    CrossrefPubMedGoogle Scholar
  • 75 Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R, Lehnert H. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003; 88: 5150-5157
    CrossrefPubMedGoogle Scholar
  • 76 Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A, Renzullo A, Bellastella G, Colao A, Vallone G, Bellastella A, Sinisi AA. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008; 40: 263-271
    PubMedGoogle Scholar
  • 77 Li M, Kong ZM, Liu ZL. Antioxidant enzyme activities and lipid peroxidation induced by eicosapentaenoic acid (EPA) in PC12 cells. Cell Biol Toxic 2006; 22: 331-337
    PubMedGoogle Scholar
  • 78 Senzaki H, Iwamoto S, Ogura E, Kiyozuka Y, Arita S, Kurebayashi J, Takada H, Hioki K, Tsubura A. Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro. Anticancer Res 1998; 18: 1621-1627
    PubMedGoogle Scholar
  • 79 Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Current medicinal chemistry Anti-cancer agents 2003; 3: 271-290
    PubMedGoogle Scholar
  • 80 Martiniova L, Cleary S, Lai EW, Kiesewetter DO, Seidel J, Dawson LF, Phillips JK, Thomasson D, Chen X, Eisenhofer G, Powers JF, Kvetnansky R, Pacak K. Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nucl Med Biol 2012; 39: 215-226
    CrossrefPubMedGoogle Scholar
  • 81 Giubellino A, Woldemichael GM, Sourbier C, Lizak MJ, Powers JF, Tischler AS, Pacak K. Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Lett 2012; 316: 46-52
    CrossrefPubMedGoogle Scholar